Less than two days after Amgen Inc. said it was picking up a Phase II-stage drug for chronic kidney disease through the acquisition of Ilypsa Inc., the biotech giant announced plans to swallow another small biotech, Alantos Pharmaceuticals Inc., for $300 million cash. (BioWorld Today)